Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 20/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14565224 | 0.78 | CYP19A1 (0.48) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL9945342 | 0.76 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL946685 | 0.74 | CYP19A1 (0.64) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL29079510 | 0.72 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL178028 | 0.72 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL5326636 | 0.72 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL4331 | 0.72 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL9196331 | 0.72 | CYP19A1 (0.68) | CYP19A1CYP11B1CYP11B2 | |
| Letrozole SCHEMBL28081077 | 0.71 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL1026263 | 0.71 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0408509-B1 | Substituted benzonitriles | CIBA GEIGY AG (CH) | 1996-03-06 | — | — | EP | claimed |
| US-5073574-A | TETRAZOLYL SUBSTITUTED BENZONITRILES AND ANTI-TUMOR USE THEREOF | CIBA-GEIGY CORPORATION (US) | 1991-12-17 | — | — | US | claimed |
| EP-0408509-A2 | Substituted benzonitriles | CIBA-GEIGY AG (CH) | 1991-01-16 | — | — | EP | claimed |
| US-20210109085-A1 | METHODS FOR PREDICTING ER-MEDIATED DNA DAMAGE | UNIVERSITY OF MASSACHUSETTS | 2021-04-15 | — | — | US | disclosed |
| US-8871750-B2 | Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus | WAYNE STATE UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8008333-B2 | Inducing ovulation; increasing response to follicle stimulating hormone | ARES TRADING S.A. (CH) | 2011-08-30 | — | — | US | disclosed |
| US-7846957-B2 | Aromatase inhibition to enhance assisted reproduction | ARES TRADING S.A. (CH) | 2010-12-07 | — | — | US | disclosed |
| US-7820706-B2 | Multiple dose aromatase inhibitor for treating infertility | ARES TRADING S.A. (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CASPER ROBERT F | 2010-04-29 | — | — | US | disclosed |
| EP-1898923-A4 | AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION | CASPER ROBERT F (CA) | 2009-05-20 | — | — | EP | disclosed |
| EP-1804805-A4 | USE OF AROMATASE INHIBITORS FOR THE TREATMENT OF ECTOPIC PREGNANCY | UNIV WAYNE STATE (US) | 2008-08-13 | — | — | EP | disclosed |
| US-5637605-A | ANTITUMOR AGENTS | CIBA GEIGY CORPORATION (US) | 1997-06-10 | — | — | US | disclosed |
| US-5583128-A | ADMINISTERING A SIDE EFFECT REDUCED AROMATASE INHIBITOR | CIBA-GEIGY CORPORATION (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0408509-B1 | Substituted benzonitriles | CIBA GEIGY AG (CH) | 1996-03-06 | — | — | EP | disclosed |
| US-5457209-A | Antitumor agents | CIBA-GEIGY CORPORATION (US) | 1995-10-10 | — | — | US | disclosed |
| US-5376669-A | Antitumor agents | CIBA-GEIGY CORP. (US) | 1994-12-27 | — | — | US | disclosed |
| US-5227393-A | estrogen-dependent diseases, anticancer | CIBA-GEIGY CORPORATION (US) | 1993-07-13 | — | — | US | disclosed |
| EP-0490816-A2 | Fluoro-compounds | CIBA-GEIGY AG (CH) | 1992-06-17 | — | — | EP | disclosed |
| US-5073574-A | TETRAZOLYL SUBSTITUTED BENZONITRILES AND ANTI-TUMOR USE THEREOF | CIBA-GEIGY CORPORATION (US) | 1991-12-17 | — | — | US | disclosed |
| EP-0408509-A2 | Substituted benzonitriles | CIBA-GEIGY AG (CH) | 1991-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CYP19A1, SHBG, HSD17B11 | CYP19A1 1/4885CYP3A4 32/4885CYP11B1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.